pharmaphorum Daily newsletter - 6th Feb.
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
This Thursday, the pharma group Partnership for Safe Medicines has slammed a Hims & Hers advertisement prepped for the Super Bowl kick-off this weekend, claiming it is ‘reckless’ promotion of its compounded weight-loss drug semaglutide.
Elsewhere, after its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track, and Newel Health has been granted EU certification for its VR-based digital therapeutic for chronic pain, clearing the way for its launch in Europe.
Meanwhile, BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2,200 job cuts, adding a target of another $2bn by end of 2027, and AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared.
And in our longer reads today, dive into further industry predictions for the year ahead, discover more about antibody drugs, and delve into wider context behind NICE cost-effectiveness thresholds. A summative podcast on JPM 2025 also airs today: catch editor-in-chief Jonah Comstock and our Deep Dive editor Eloise McLennan chat through what was what at the event.
All this and more on pharmaphorum.com.
News
Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."
After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track.
Newel Health has been granted EU certification for its VR-based digital therapeutic for chronic pain, clearing the way for its launch in Europe.
BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2200 job cuts, adding a target of another $2bn by end-2027.
AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared.
Views & Analysis
Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their case for change
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials.
Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become indispensable tools in modern medicine.
The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as a genetic instruction book, telling cells to produce therapeutic or protective proteins, eliminating the need to administer proteins directly. Although this branch of medicine is still young, it has already shown enormous potential, and many more LNP-mRNA therapeutics are on the horizon. However, this modality creates unique bioanalysis requirements and challenges.
领英推荐
Axtria Rapid CSR transforms clinical study reporting by streamlining the entire CSR authoring workflow, combining the power of artificial intelligence with human expertise to deliver superior results. Find out more in a new Solution Spotlight from Axtria.
Podcasts & Videos
In this special extended episode of the pharmaphorum podcast, Jonah sits down with Deep Dive editor, Eloise McLennan, to break down the key themes and takeaways from this year’s event in San Francisco.
At JPM Week 2025 in San Francisco, pharmaphorum editor-in-chief Jonah Comstock met with Rick Stewart, CEO of Achieve Life Sciences, a biotech developing a new treatment for nicotine addiction with comparable efficacy and fewer side effects than the leading competitors.
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Dr James Field, founder and CEO of LabGenius, a drug discovery company pioneering the discovery of next-generation therapeutic antibodies in order to solve this predicament.
REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early days it focused on licensing its NAV Technology platform to other companies.)
In a new pharmaphorum podcast with ZS Associates’ Sharon Karlsberg, principal and leader of oncology solutions, and Brandi Davis-Dusenbery, principal and partner, web editor Nicole Raleigh explores the potential for scaling advanced technologies in the biopharmaceutical industry.
Webinars & White Papers
Rare diseases often leave patients, healthcare professionals, and pharma companies navigating complex challenges, from limited treatment options to high costs and difficult clinical trial development. Cell and gene therapies (CGTs) offer a unique opportunity to address these challenges by treating diseases at their genetic or cellular roots. In this webinar, sponsored by IPG Health, discover how industry insiders are unlocking the potential of CGTs in rare disease care, the unique hurdles facing pharma and patients, and the transformative opportunities these therapies bring.
In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication planners and medical affairs communications teams can leverage the new impact metrics that matter for journal selection.
In a recent webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possible’, this forward-looking session explored how imagination and innovation are reshaping the future of healthcare. Available now on demand.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the endeavours and developments that occurred since inaugural discussions 2023.
A panel of experts, including from IPG Health, have shared their sector experience and wisdom in a new 60 Seconds white paper, ‘Moments of Truth: Launch’, to highlight the need to create and champion an organisational culture that underwrites a new product’s potential.